David Braun, MD, PhD, Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar, and Nazli Dizman, MD, a resident in internal medicine at Yale School of Medicine, have both received Trailblazer Awards from the Kidney Cancer Association. The awards support researchers pursuing projects with the potential to improve kidney cancer treatment and care.
Dr. Braun cares for patients with kidney cancer and his research primarily focuses on integrating experimental and computational approaches to biomedical research. He is also a member of the Center of Molecular and Cellular Oncology at Yale. His project is titled, “Dissecting the immunobiology of chromophobe renal cell carcinoma using single-cell transcriptomics.”
Dr. Dizman’s research is focused on molecular targeted therapy, drug-related side effects and adverse reactions, and looking at the gastrointestinal microbiome. Dr. Dizman recently led a study assessing the impact of dietary interventions on gut microbiome in patients with metastatic renal cell carcinoma receiving immunotherapies. Her current project is titled, “Impact of CBM588 on metabolomic profile in patients with metastatic renal cell carcinoma (mRCC).”
The Trailblazer Award is a new award category from the Kidney Cancer Association this year and funds promising young- to mid-career investigators to foster innovative kidney cancer research. The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding the cure for kidney cancer.